U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
Machine learning approach to systems biology combined with ligand discovery platform
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Subscribe To Our Newsletter & Stay Updated
